167 related articles for article (PubMed ID: 33167328)
21. Hepatocyte nuclear receptor SHP suppresses inflammation and fibrosis in a mouse model of nonalcoholic steatohepatitis.
Zou A; Magee N; Deng F; Lehn S; Zhong C; Zhang Y
J Biol Chem; 2018 Jun; 293(22):8656-8671. PubMed ID: 29666185
[TBL] [Abstract][Full Text] [Related]
22. The indole derivative NecroX-7 improves nonalcoholic steatohepatitis in ob/ob mice through suppression of mitochondrial ROS/RNS and inflammation.
Chung HK; Kim YK; Park JH; Ryu MJ; Chang JY; Hwang JH; Lee CH; Kim SH; Kim HJ; Kweon GR; Kim KS; Shong M
Liver Int; 2015 Apr; 35(4):1341-53. PubMed ID: 25443620
[TBL] [Abstract][Full Text] [Related]
23. Peroxisome proliferator-activated receptor-delta agonist ameliorated inflammasome activation in nonalcoholic fatty liver disease.
Lee HJ; Yeon JE; Ko EJ; Yoon EL; Suh SJ; Kang K; Kim HR; Kang SH; Yoo YJ; Je J; Lee BJ; Kim JH; Seo YS; Yim HJ; Byun KS
World J Gastroenterol; 2015 Dec; 21(45):12787-99. PubMed ID: 26668503
[TBL] [Abstract][Full Text] [Related]
24. A specific amino acid formula prevents alcoholic liver disease in rodents.
Tedesco L; Corsetti G; Ruocco C; Ragni M; Rossi F; Carruba MO; Valerio A; Nisoli E
Am J Physiol Gastrointest Liver Physiol; 2018 May; 314(5):G566-G582. PubMed ID: 29368944
[TBL] [Abstract][Full Text] [Related]
25. Palmitic Acid Hydroxystearic Acids Activate GPR40, Which Is Involved in Their Beneficial Effects on Glucose Homeostasis.
Syed I; Lee J; Moraes-Vieira PM; Donaldson CJ; Sontheimer A; Aryal P; Wellenstein K; Kolar MJ; Nelson AT; Siegel D; Mokrosinski J; Farooqi IS; Zhao JJ; Yore MM; Peroni OD; Saghatelian A; Kahn BB
Cell Metab; 2018 Feb; 27(2):419-427.e4. PubMed ID: 29414687
[TBL] [Abstract][Full Text] [Related]
26. Intracellular and extracellular miRNome deregulation in cellular models of NAFLD or NASH: Clinical implications.
Di Mauro S; Ragusa M; Urbano F; Filippello A; Di Pino A; Scamporrino A; Pulvirenti A; Ferro A; Rabuazzo AM; Purrello M; Purrello F; Piro S
Nutr Metab Cardiovasc Dis; 2016 Dec; 26(12):1129-1139. PubMed ID: 27756518
[TBL] [Abstract][Full Text] [Related]
27. Decreasing mitochondrial fission alleviates hepatic steatosis in a murine model of nonalcoholic fatty liver disease.
Galloway CA; Lee H; Brookes PS; Yoon Y
Am J Physiol Gastrointest Liver Physiol; 2014 Sep; 307(6):G632-41. PubMed ID: 25080922
[TBL] [Abstract][Full Text] [Related]
28. Lipid-induced up-regulation of human acyl-CoA synthetase 5 promotes hepatocellular apoptosis.
Reinartz A; Ehling J; Leue A; Liedtke C; Schneider U; Kopitz J; Weiss T; Hellerbrand C; Weiskirchen R; Knüchel R; Gassler N
Biochim Biophys Acta; 2010 Sep; 1801(9):1025-35. PubMed ID: 20470896
[TBL] [Abstract][Full Text] [Related]
29. Protective effect of the Y220C mutant p53 against steatosis: good news?
Gori M; Barbaro B; Arciello M; Maggio R; Viscomi C; Longo A; Balsano C
J Cell Physiol; 2014 Sep; 229(9):1182-92. PubMed ID: 24395441
[TBL] [Abstract][Full Text] [Related]
30. Raman Study on Lipid Droplets in Hepatic Cells Co-Cultured with Fatty Acids.
Paramitha PN; Zakaria R; Maryani A; Kusaka Y; Andriana BB; Hashimoto K; Nakazawa H; Kato S; Sato H
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34298998
[TBL] [Abstract][Full Text] [Related]
31. Free fatty acids sensitise hepatocytes to TRAIL mediated cytotoxicity.
Malhi H; Barreyro FJ; Isomoto H; Bronk SF; Gores GJ
Gut; 2007 Aug; 56(8):1124-31. PubMed ID: 17470478
[TBL] [Abstract][Full Text] [Related]
32. Up-regulation of hepatic fatty acid transporters and inhibition/down-regulation of hepatic OCTN2 contribute to olanzapine-induced liver steatosis.
Jiang T; Zhang Y; Bai M; Li P; Wang W; Chen M; Ma Z; Zeng S; Zhou H; Jiang H
Toxicol Lett; 2019 Nov; 316():183-193. PubMed ID: 31437515
[TBL] [Abstract][Full Text] [Related]
33. [The relationship between the opening of mitochondrial permeability transition pores of cultured hepatocytes with their apoptoses in a non-alcoholic fatty liver disease model].
Chen DF; Wang CH
Zhonghua Gan Zang Bing Za Zhi; 2007 Nov; 15(11):837-9. PubMed ID: 18073067
[TBL] [Abstract][Full Text] [Related]
34. Phenylmethimazole abrogates diet-induced inflammation, glucose intolerance and NAFLD.
Patton A; Church T; Wilson C; Thuma J; Goetz DJ; Berryman DE; List EO; Schwartz F; McCall KD
J Endocrinol; 2018 Jun; 237(3):337-351. PubMed ID: 29666152
[TBL] [Abstract][Full Text] [Related]
35. Targeted Delivery of Stk25 Antisense Oligonucleotides to Hepatocytes Protects Mice Against Nonalcoholic Fatty Liver Disease.
Cansby E; Nuñez-Durán E; Magnusson E; Amrutkar M; Booten SL; Kulkarni NM; Svensson LT; Borén J; Marschall HU; Aghajan M; Mahlapuu M
Cell Mol Gastroenterol Hepatol; 2019; 7(3):597-618. PubMed ID: 30576769
[TBL] [Abstract][Full Text] [Related]
36. Prevention of free fatty acid-induced hepatic lipotoxicity by carnitine via reversal of mitochondrial dysfunction.
Jun DW; Cho WK; Jun JH; Kwon HJ; Jang KS; Kim HJ; Jeon HJ; Lee KN; Lee HL; Lee OY; Yoon BC; Choi HS; Hahm JS; Lee MH
Liver Int; 2011 Oct; 31(9):1315-24. PubMed ID: 22093454
[TBL] [Abstract][Full Text] [Related]
37. Time-dependent changes and association between liver free fatty acids, serum lipid profile and histological features in mice model of nonalcoholic fatty liver disease.
Stanković MN; Mladenović DR; Duričić I; Šobajić SS; Timić J; Jorgačević B; Aleksić V; Vučević DB; Ješić-Vukićević R; Radosavljević TS
Arch Med Res; 2014 Feb; 45(2):116-24. PubMed ID: 24480733
[TBL] [Abstract][Full Text] [Related]
38. Targeting alkaline ceramidase 3 alleviates the severity of nonalcoholic steatohepatitis by reducing oxidative stress.
Wang K; Li C; Lin X; Sun H; Xu R; Li Q; Wei Y; Li Y; Qian J; Liu C; Zhang Q; Yu S; Cui Z; Huang X; Zhu B; Zhou J; Mao C
Cell Death Dis; 2020 Jan; 11(1):28. PubMed ID: 31949129
[TBL] [Abstract][Full Text] [Related]
39. Hepatic FTO expression is increased in NASH and its silencing attenuates palmitic acid-induced lipotoxicity.
Lim A; Zhou J; Sinha RA; Singh BK; Ghosh S; Lim KH; Chow PK; Woon ECY; Yen PM
Biochem Biophys Res Commun; 2016 Oct; 479(3):476-481. PubMed ID: 27651333
[TBL] [Abstract][Full Text] [Related]
40. Arctigenin protects against steatosis in WRL68 hepatocytes through activation of phosphoinositide 3-kinase/protein kinase B and AMP-activated protein kinase pathways.
Chen KY; Lin JA; Yao HY; Hsu AC; Tai YT; Chen JT; Hsieh MC; Shen TL; Hsu RY; Wu HT; Wang GH; Ho BY; Chen YP
Nutr Res; 2018 Apr; 52():87-97. PubMed ID: 29525610
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
